Lakefront Biotherapeutics (LKFT) Cash from Financing Activities (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash from Financing Activities for 11 consecutive years, with -$580356.7 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Financing Activities rose 49.55% year-over-year to -$580356.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (up 41.85% YoY) and the FY2025 annual result came in at -$3.7 million, up 33.53% from the prior year.
• Cash from Financing Activities declined to -$580356.7 in Q1 2026 per LKFT's latest filing, from -$460871.5 in the prior quarter.
• Over the last five years, Cash from Financing Activities for LKFT reached as high as -$28448.9 in Q1 2022 and fell as low as -$2.2 million in Q4 2022.
• A 5-year average of -$1.1 million and a median of -$1.2 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 660.0% — and 2025, when it soared 74.75%.
• Year by year, Cash from Financing Activities stood at -$2.2 million in 2022, then soared by 37.94% to -$1.4 million in 2023, then tumbled by 34.68% to -$1.8 million in 2024, then surged by 74.75% to -$460871.5 in 2025, then fell by 25.93% to -$580356.7 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$580356.7, -$460871.5, and -$1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.